Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation

Molecular and Cellular Biology

Volumn 18, Issue 11, 1998, Pages 6795-6804

  Danial, Nika N ^a   Losman, Julie A ^a   Lu, Tianhong ^a   Yip, Natalie ^a   Krishnan, Kartik ^a   Krolewski, John ^a   Goff, Stephen P ^a   Wang, Jean Y J ^b   Rothman, Paul B ^a,c  

^a The New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; HYBRID PROTEIN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CELL MATURATION; GENE EXPRESSION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUDE MOUSE; ONCOGENE; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS TRANSCRIPTION;

EID: 0031741655     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.11.6795     Document Type: Article

References (59)

1. Burfoot, M. S., N. C. Rogers, D. Watling, J. M. Smith, S. Pons, G. Paonessaw, S. Pellegrini, M. F. White, and I. M. Kerr. 1997. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J. Biol. Chem. 272:24183-24190.
2. Campbell, G., C. L. Yu, R. Jove, and C. Carter-Su. 1997. Constitutive activation of JAK1 in Src-transformed cells. J. Biol. Chem. 272:2591-2594.
3. Cao, X., A. Tay, G. R. Guy, and Y. H. Tan. 1996. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16:1595-1603.
4. Carlesso, N., D. A. Frank, and J. D. Griffin. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183:811-820.
5. Chai, S. K., G. L. Nichols, and P. Rothman. 1997. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived form leukemic patients. J. Immunol. 159:4720-4728.
6. Chaturvedi, P., S. Sharma, and E. P. Reddy. 1997. Abrogation of interleukin-3 dependence of rhyeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol. 17:3295-3304.
7. Chen, S.-C., D. Redenius, J. C. Young, and R. C. Schwartz. 1993. Synergy of IL-7 and v-Ha-ras in the in vitro neoplastic progression of murine pre-B cells. Oncogene 8:2119-2125.
8. Cleveland, J. L., M. Dean, N. Rosenberg, J. Y. J. Wang, and U. R. Rapp. 1989. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving e-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol. Cell. Biol. 9:5685-5695.
9. Danial, N. N., A. Pernis, and P. B. Rothman. 1995. Jak-STAT signaling induced by the v-Abl oncogene. Science 269:1875-1877.
10. Danial, N. N., and P. B. Rothman. Unpublished results.
11. de Rooij, J., and J. L. Bos. 1997. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14:623-625.
12. Dorsch, M., P.-D. Fan, N. N. Danial, P. B. Rothman, and S. P. Goff. 1997. The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway. J. Exp. Med. 186:1947-1955.
13. Downward, J. 1997. Role of phosphoinositide-3-OH kinase in Ras signaling. Adv. Second Messenger Phosphoprotein Res. 31:1-10.
14. Ellis, C., M. Moran, F. McCormick, and T. Pawson. 1990. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 343:377-381.
15. c-Fes. J. Biol. Chem. 269:5764-5769.
16. Fainstein, E., M. Einat, E. Gokkel, C. Marcelle, C. M. Croce, R. P. Gale, and E. Canaani. 1989. Nucleotide sequence analysis of human ABL and BCR-ABL cDNAs. Oncogene 4:1477-1481.
17. Feller, S. M., B. Knudsen, and H. Hanafusa. 1994. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 13:2341-2351.
18. Frangioni, J. V., and B. G. Neel. 1993. Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal. Biochem. 210:179-187.
19. Garcia, R., and R. Jove. 1998. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5:79-85.
20. Hanratty, W. P., and C. R. Dearolf. 1993. The Drosophila tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus. J. Gen. Genet. 238:33-37.
21. Harrison, D. A., R. Binari, T. S. Nahreini, M. Gilman, and N. Perrimon. 1995. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 14:2857-2865.
22. Hevezi, P., K. Alin, and S. P. Goff. 1993. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-Abl and v-src oncogenes. Oncogene 8:2413-2423.
23. Huebner, R. C., A. Engelman, L. Schiff, and N. Rosenberg. 1988. Abelson virus sequences important in lymphoid transformation, p. 257-270. In N. Klineman, O. N. Witte, and M. Howard (ed.), B cell development. Raven Press, New York, N.Y.
24. BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704-31710.
25. Jackson, P., and D. Baltimore. 1989. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:449-456.
26. Kipreos, E. T., and J. Y. J. Wang. 1992. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256:382-385.
27. Kipreos, E. T., and J. Y. J. Wang. 1990. Differential phosphorylation of c-Abl tyrosine kinase in cell cycle determined by cdc2 kinase and phosphatase activity. Science 248:217-220.
28. Krishnan, K., R. Pine, and J. J. Krolewski. 1997. Kinase-deficient forms of Jak 1 and Tyk 2 inhibit interferon α signaling in a dominant manner. Eur. J. Biochem. 247:298-305.
29. Lacronique, V., A. Boureux, V. Della Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-1312.
30. Leonard, W. J., and J. J. O'Shea. 1998. JAKS and STATS: biological implications. Annu. Rev. Immunol. 16:293-322.
31. Mathey-Prevot, B., G. Nabel, R. Palacios, and D. Baltimore. 1986. Abelson virus abrogation of interleukin-3 dependence in a lymphoid cell line. Mol. Cell. Biol. 6:4133-4135.
32. Mayer, B. J., P. K. Jackson, R. A. Van Etten, and D. Baltimore. 1992. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:609-618.
33. McWhirther, J. R., and J. Y. J. Wang. 1991. Activation of tyrosine kinase and microfilament-binding functions of c-Abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11:1553-1565.
34. Miao, Y.-J., and J. Y. J. Wang. 1996. Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase. J. Biol. Chem. 271: 22823-22830.
35. Murtach, K., G. Skladany, J. Hoag, and N. Rosenberg. 1986. Abelson murine leukemia virus variants with increased oncogenic potential. J. Virol. 60:599-606.
36. O'Shea, J. J. 1997. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7:1-11.
37. Owen-Lynch, P. J., A. K. Y. Wong, and A. D. Whetton. 1995. v-Abl-mediated apoptosis suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation. J. Biol. Chem. 270: 5956-5962.
38. Parmar, K., and N. Rosenberg. 1996. Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation. J. Virol. 70:1009-1015.
39. Peeters, P., S. D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. V. Rompaey, M. Baens, H. Van den Berghe, and P. Marynen. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase Jak2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:2535-2540.
40. Pendergast, A. M., J. A. Traugh, and O. N. Witte. 1987. Normal cellular and transformation-associated abl proteins share common sites for protein kinase C phosphorylation. Mol. Cell. Biol. 7:4280-4289.
41. Pendergast, A. M., L. A. Quilliam, L. D. Cripe, G. H. Bassing, Z. Dai, N. Li, A. Batzer, K. M. Rabun, C. J. Der, J. Schlessinger, and M. Gishizky. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 75:175-185.
42. Prywes, R., J. G. Foulkes, N. Rosenberg, and D. Baltimore. 1983. Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell 34:569-579.
43. Prywes, R., J. Hoag, N. Rosenberg, and D. Baltimore. 1985. Protein stabilization explains the gag requirement for transformation of lymphoid cells by Abelson murine leukemia virus. J. Virol. 54:123-132.
44. Ren, R., Z.-S. Ye, and D. Baltimore. 1994. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 8:783-795.
45. Renshaw, M. W., E. T. Kipreos, M. R. Albrecht, and J. Y. J. Wang. 1992. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth depending on the cell context. EMBO J. 11:3941-3951.
46. Renshaw, M. W., E. Lea-Chou, and J. Y. J. Wang. 1995. Rac is required for v-Abl tyrosine kinase to activate mitogenesis. Curr. Biol. 6:76-83.
47. Rosenberg, N. 1994. abl-mediated transformation, immunoglobulin gene rearrangements and arrest of B lymphocyte differentiation. Semin. Cancer Biol. 5:95-102.
48. Rosenberg, N., and O. N. Witte. 1980. Abelson murine leukemia virus mutants with alteration in the virus-specific p120 molecule. J. Virol. 33:340-348.
49. Sawyers, C. L., W. Callahan, and O. N. Witte. 1992. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70:901-910.
50. Sawyers, C. L., J. McLaughlin, and O. N. Witte. 1995. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181:307-313.
51. Shi, Y., K. Alin, and S. P. Goff. 1995. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-Abl transforming activity. Genes Dev. 9:2583-2597.
52. Shuai, K., J. Halpern, J. T. Hoeve, X. Rao, and C. L. Sawyers. 1996. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-254.
53. Van Beveren, C., J. Coffin, and S. Hughes. 1985. Pages 852-866. In R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses, vol. 2. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
54. Van Etten, R. A., P. K. Jackson, D. Baltimore, M. C. Sanders, P. T. Matsudaira, and P. A. Janmey. 1989. The COOH terminus of the c-Abl tyrosine kinase contains distinct F-and G-actin binding domains with bundling activity. J. Cell Biol. 124:235-240.
55. Varticovski, L., G. Q. Daley, P. Jackson, D. Baltimore, and L. C. Cantley. 1991. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol. Cell. Biol. 11:1107-1113.
56. Welch, P. J., and J. Y. J. Wang. 1993. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75:779-790.
57. Winston, L. A., and T. Hunter. 1996. Intracellular signalling: putting JAKs on the kinase MAP. Curr. Biol. 6:668-671.
58. Yamanashi, Y., and D. Baltimore. 1997. Identification of the Abl and ras-GAP-associated 62 kDa protein as a docking protein, Dok. Cell 88:205-211.
59. Young, J. C., M. L. Gishizky, and O. N. Witte. 1991. Hyperexpression of interleukin-7 is not necessary or sufficient for transformation of a pre-B-lymphoid cell line. Mol. Cell. Biol. 11:854-863.